Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$1.31M Buy
54,296
+4,298
+9% +$112K 0.02% 150
2026
Q1
$1.41M Buy
49,998
+22,000
+79% +$586K 0.02% 145
2025
Q4
$695K Buy
27,998
+15,325
+121% +$386K 0.01% 177
2025
Q3
$322K Buy
+12,673
New +$313K ﹤0.01% 219
2024
Q4
Sell
-6,973
Closed -$201K 166
2024
Q3
$201K Buy
+6,973
New +$203K ﹤0.01% 155
2024
Q1
Sell
-11,507
Closed -$333K 162
2023
Q4
$333K Sell
11,507
-715
-6% -$21.6K 0.01% 149
2023
Q3
$406K Buy
+12,222
New +$432K 0.01% 136

Other funds holding PFE

ABN AMRO Bank's PFE Position: Q2 2026 in Review

ABN AMRO Bank increased its Pfizer (PFE) stake by 8.6% in Q2 2026, buying an estimated $112K and bringing the position to 54,296 shares worth $1.31M. The position accounts for 0.02% of the portfolio, ranked #150.

ABN AMRO Bank first reported a position in PFE in Q3 2023 and has held it in 7 quarters since. The position peaked at $1.41M in Q1 2026. 2,823 funds tracked by Wall St. Rank hold PFE as of Q2 2026.

  • ABN AMRO Bank held 54,296 shares of Pfizer worth $1.31M as of Q2 2026.
  • ABN AMRO Bank bought 4,298 Pfizer shares in Q2 2026, an estimated $112K.
  • Pfizer made up 0.02% of ABN AMRO Bank's portfolio in Q2 2026, its #150 holding.
  • ABN AMRO Bank first reported a position in Pfizer in Q3 2023 and has held it in 7 quarters since.
  • ABN AMRO Bank's Pfizer position peaked at $1.41M in Q1 2026.
  • 2,823 funds tracked by Wall St. Rank held Pfizer as of Q2 2026.

Based on ABN AMRO Bank's 13F filing for Q2 2026, filed 6 Aug 2026.